Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 2, 2004, Pages 167-177

  Simonson, Steven G ^a   Raza, Ali ^a   Martin, Paul D ^a   Mitchell, Patrick D ^a   Jarcho, John A ^b   Brown, Colin D A ^c   Windass, Amy S ^c   Schneck, Dennis W ^a  

^a ASTRAZENECA   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; ORGANIC ANION TRANSPORTER; PREDNISONE; ROSUVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; GEOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; ISOTOPE LABELING; MALE; MYOPATHY; OOCYTE; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; XENOPUS;

ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OOCYTES; PYRIMIDINES; SULFONAMIDES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; XENOPUS;

EID: 3542992126     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.03.010     Document Type: Article

References (32)

1. Martin J., Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class. Are they relevant? Drug Saf. 26:2003;13-21
2. Åsberg A., Hartmann A., Fjeldså E., Bergan S., Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 1:2001;382-386
3. Arnadottir M., Eriksson L.O., Thysell H., Karkas J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 65:1993;410-413
4. Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 62:1997;311-321
5. Regazzi M.B., Iacona I., Campana C., Raddato V., Lesi C., Perani G., et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25:1993;2732-2734
6. Mück W., Mai I., Fritsche L., Ochmann K., Rohde G., Unger S., et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 65:1999;251-261
7. Park J.W., Siekmeier R., Lattke P., Merz M., Mix C., Schuler S., et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther. 6:2001;351-361
8. Konig J., Cui Y., Nies A.T., Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 278:2000;G156-164
9. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 274:1999;37161-37168
10. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 297:2001;861-867
11. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 304:2003;610-616
12. Brown C.D.A., Windass A., Bleasby K., Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract]. Atheroscler Suppl. 2:2001;90
13. Brewer H.B. Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 92:2003;23K-29K
14. Schneck D.W., Knopp R.H., Ballantyne C.M., McPherson R., Chitra R.R., Simonson S.G. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 91:2003;33-41
15. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 93:2003;152-160
16. McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., Blasetto J.W., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals results from the STELLAR trial. Curr Med Res. 19:2003;689-698
17. Martin P.D., Warwick M.J., Dane A.L., Hill S.J., Giles P.B., Phillips P.J., et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 25:2003;2822-2835
18. McCormick A.D., McKillop D., Butters C.J., Miles G.S., Baba T., Touchi A., et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol. 40:2000;1055
19. Martin P.D., Warwick M.J., Dane A.L., Brindley C., Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 25:2003;2553-2563
20. Martin P.D., Mitchell P.D., Schneck D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 54:2002;472-477
21. Hull C.K., Penman A.D., Smith C.K., Martin P.D. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 772:2002;219-228
22. Myers G.L., Cooper C.R., Winn C.L., Smith S.J. The Centers for Disease Control - National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements. Clin Lab Med. 9:1989;105-135
23. Nezasa K., Higaki K., Takeuchi M., Nakano M., Koike M. Uptake of rosuvastatin by isolated rat hepatocytes comparison with pravastatin. Xenobiotica. 33:2003;379-388
24. Martin P.D., Dane A.L., Nwose O.M., Schneck D.W., Warwick M.J. No effect of age or gender on the pharmacokinetics of rosuvastatin a new HMG-CoA reductase inhibitor. J Clin Pharmacol. 42:2002;1116-1121
25. Stapf V., Thalhammer T., Huber-Huber R., Felberbauer F., Gajdzik L., Graf J. Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. Anticancer Res. 14:1994;581-585
26. Hebert M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 27:1997;201-214
27. Huang L, Zalikowski J, Dudley A, Grimm S, Wang Y. Investigation of P-glycoprotein-mediated transport of rosuvastatin acid and its lactone across MDR1-MDCK cell monolayers. Presented as a poster at the annual meeting of the American Association of Pharmaceutical Scientists; 2003 Oct 26-30; Salt Lake City, Utah
28. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., Cantarini M.V. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 73:2003;322-329
29. Martin P.D., Kemp J., Dane A.L., Warwick M.J., Schneck D.W. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 42:2002;1352-1357
30. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin. Br J Clin Pharmacol. 55:2003;94-99
31. Yamazaki M., Akiyama S., Ni'inuma K., Nishigaki R., Sugiyama Y. Biliary excretion of pravastatin in rats contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 25:1997;1123-1129
32. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., Schneck D.W. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 59:2003;51-56